The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery (CAPTAIN)
A Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury
Sponsor: Ever Neuro Pharma GmbH
Terminated
Poor patient recruitment
Other terminated trials from Ever Neuro Pharma GmbH
More terminations from Ever Neuro Pharma GmbH
Other Traumatic Brain Injury trials with similar outcome
A PHASE4 clinical study on Traumatic Brain Injury, this trial is terminated or withdrawn. The trial is conducted by Ever Neuro Pharma GmbH and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Jun 2018 — Mar 2020 [monthly]
Unknown Status PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ever Neuro Pharma GmbH
For direct contact, visit the study record on ClinicalTrials.gov .